Dr. Abdul Abdellatif
Total: 10 projects
-
2007 – 2008 Affymax, Inc. – Site Principle investigator. “AFX01-14: A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin”
-
2007 – 2008 Effect of treatment of vitamin D Deficiency/Insufficiency on mineral metabolism in non-dialyzed patients with CKD
Abstract/Poster National Kidney Foundation -
2008 – present Fibrogen, Inc. – Site Principle investigator. “A Randomized, Single-blind, Placebo-controlled, 4-Week Treatment Study of the Safety and Biologic Activity of Escalating Multiple Oral Doses of FG-4592 in Subjects with Chronic Kidney Disease Not Requiring Dialysis”
-
2007 – present Novartis Pharmaceutical – Site Principle investigator: “A multi-canter, randomized, double-blind, active-controlled clinical trial to evaluate the safety and tolerability of 24 weeks treatment with Vildagliptin (50 mg qd) versus Sitagliptin (25 mg qd) in patients with type 2 diabetes and severe renal insufficiency” Abdul Ali Abdellatif
-
2007 – present Keryx Pharmaceuticals,Inc.- Site Principle Investigator "The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy"
-
2007 – present NIH - Sub-Investigator "Focal Segmental Glomerulosclerosis (FSGS) Clinical Trial"
-
2007 – present NIH/Abbott Laboratories - Sub-Investigator "Dietary Protein Requirements in Hemodialysis Patients"
-
2007 – present Baylor - Sub-Investigator "Renal Outpatient and Inpatient Database"
-
ALTITUDE SPP100: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO DETERMINE WHETHER, IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK FOR CARDIOVASCULAR AND RENAL EVENTS, ALISKIREN, ON TOP OF CONVENTIONAL TREATMENT, REDUCES CARDIOVASCULAR AND RENAL MORBIDITY AND MORTALITY
-
"Ischemic Pancreatitis and Antiphospholipid Syndrome" Abstract/posterAmerican College of Physicians (APS) Dallas Texas 2008
